论文部分内容阅读
目的:观察转移性结直肠癌采用化疗联合分子靶向药物的疗效。方法:选取本院收治的96例转移性结直肠癌患者,随机分组。对照组患者接受FOLFIRI方案化疗,实验组患者在此基础上辅以分子靶向药物西妥昔单抗治疗,对比两组患者治疗效果和骨髓抑制毒副反应的差异性。结果:实验组患者临床控制率明显高于对照组,差异有统计学意义。两组患者严重骨髓抑制毒副反应发生率组间差异无统计学意义。结论:采用化疗联合分子靶向药物的疗效转移性结直肠癌疗效满意,且不会加重毒副反应的严重程度,值得在临床推广应用。
Objective: To observe the efficacy of chemotherapy combined with molecular targeted drugs in metastatic colorectal cancer. Methods: A total of 96 patients with metastatic colorectal cancer admitted to our hospital were randomly divided into groups. Patients in the control group received FOLFIRI regimen chemotherapy. Patients in the experimental group were supplemented with the molecular targeted drug cetuximab. The differences between the two groups in the treatment effect and the bone marrow suppression toxicity were compared. Results: The clinical control rate in the experimental group was significantly higher than that in the control group, the difference was statistically significant. There was no significant difference between the two groups in the incidence of severe bone marrow suppression toxicity. Conclusions: The curative effect of chemotherapy combined with molecular targeted drugs for metastatic colorectal cancer is satisfactory, and will not aggravate the severity of toxic and side effects, which is worthy of clinical application.